Disease · MONDO_0043839
Comparisons in its trials18
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 18 of 18
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Onabotulinum Toxin Type-A vs Placebo: deaths from any cause | 0 of 23 | 0 of 25 | 48 | NCT01309802 | Trial comparisons |
| Onabotulinum Toxin Type-A vs Placebo: serious adverse events | 2 of 23 | 5 of 25 | 48 | NCT01309802 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Experience Digital Ischemia Requiring Intravenous Prostacyclin or Digital Gangrene or Amputation During the Trial. | 0 of 9 | 1 of 8 | 17 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: deaths from any cause | 0 of 9 | 0 of 8 | 17 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Osteomyelitis During The Trial | 0 of 9 | 0 of 8 | 17 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: serious adverse events | 3 of 9 | 1 of 8 | 17 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Proximal Interphalangeal (PIP) Location Over the Course of the Double-blind Period. | 1 of 8 | 2 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With New Active and Indeterminate DU(s) Over the Course of the Double-blind Period | 3 of 8 | 4 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of Their Cardinal DU by Week 16 | 4 of 8 | 6 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Distal Interphalangeal (DIP) Location Over the Course of the Double-blind Period. | 0 of 8 | 1 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Elbows Over the Course of the Double-blind Period. | 0 of 8 | 0 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All DUs at Baseline by Week 16 | 3 of 8 | 3 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Proximal Interphalangeal (PIP) Over the Course of the Double-blind Period. | 1 of 8 | 0 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With no DUs at Week 16 | 2 of 8 | 2 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Metacarpophalangeal (MCPs) Over the Course of the Double-blind Period. | 0 of 8 | 0 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at Metacarpophalangeal (MCPs) Location Over the Course of the Double-blind Period. | 0 of 8 | 0 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants Who Develop Pressure Ulcers at the Elbows Over the Course of the Double-blind Period. | 0 of 8 | 0 of 8 | 16 | NCT02915835 | Trial comparisons |
| Riociguat vs Placebo: Proportion of Participants With Healing of All Pressure Ulcers at the Distal Interphalangeal (DIP) Over the Course of the Double-blind Period. | 0 of 8 | 0 of 8 | 16 | NCT02915835 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0043839/comparisons